ILDsym® is a mechanistic, mathematical model specifically developed for interstitial lung disease (ILD) associated with systemic sclerosis (SSc). This QSP modeling software enables pharmaceutical companies and researchers to conduct simulations of compounds, evaluating and modeling their efficacy while assessing effects on other key characteristics related to SSc-ILD. The software is available for in-house use through corporate software licensing. Interstitial lung disease, a severe complication of SSc, is characterized by progressive lung function loss and is linked to high morbidity and mortality. ILDsym addresses the incompletely characterized pathogenesis of SSc-ILD, which involves both endothelial and epithelial abnormalities, as well as immune and inflammatory contributors. Leveraging experience in modeling lung fibrosis, ILDsym represents inflammation and lung fibrosis in SSc-ILD, accounting for differences in clinical presentation and underlying pathophysiology compared to idiopathic pulmonary fibrosis (IPF). The software aims to make the clinical development process more efficient by combining predictions of compound exposure with pharmacodynamic characteristics to predict efficacy across diverse patient populations. ILDsym is valuable for evaluating new drug candidates as monotherapies or in combination with existing treatments, supporting the substantial efforts within the pharmaceutical industry to develop effective lung disease treatments.

Features & Benefits

• Mechanistic Modeling of SSc-ILD
  • Includes key pathophysiologic mechanisms and clinical aspects of SSc-ILD, such as inflammation, endothelial and epithelial involvement, lung fibrosis, and lung function tests (e.g., forced vital capacity–FVC).
• Detailed Lung Region Representation
  • Represents key lung regions commonly assessed by HRCT, including normal alveolar parenchyma, ground glass opacity (GGO), reticular opacity (RO), and honeycombed (HC) areas.
• Disease Progression & Patient Variability Simulation
  • Simulates disease progression and inter-patient variability in pathophysiologic and clinical characteristics using SimPops®, including therapeutic responses to mycophenolate mofetil (MMF), nintedanib, and tocilizumab (TCZ) that align with reported clinical data.
• Drug Candidate Evaluation
  • Evaluates the efficacy of potential new drug candidates for SSc-ILD as monotherapies, or in combination with and as add-on therapies to existing treatments.